{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T07:36:35Z","timestamp":1774251395456,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,22]]},"DOI":"10.7759\/cureus.105675","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T06:42:39Z","timestamp":1774248159000},"source":"Crossref","is-referenced-by-count":0,"title":["Role of Bone Turnover Markers and Bone Mineral Density in Monitoring Bone Health at One- and Three-Year Post-antiresorptive Therapy Initiation in Patients With Osteoporosis: A Retrospective Cohort Study"],"prefix":"10.7759","author":[{"given":"Ahmed T","family":"Al-Jumaily","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Batseba","family":"Bereket Araya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashiyana","family":"Malil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chakraborty","family":"Oung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavian","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tripti","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-017-4082-4 \u200b","article-title":"Use of CTX-I and P1NP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability","volume":"28","author":"Szulc P","year":"2017","unstructured":"Szulc P, Naylor K, Hoyle NR, Leary ET. Use of CTX-I and P1NP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporos Int. 2017, 28:2541-56. 10.1007\/s00198-017-4082-4 \u200b","journal-title":"Osteoporos Int"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.090310","article-title":"Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis","volume":"24","author":"Delmas PD","year":"2009","unstructured":"Delmas PD, Munoz F, Black DM, et al.. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res. 2009, 24:1544-51. 10.1359\/jbmr.090310","journal-title":"J Bone Miner Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1160","article-title":"Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study)","volume":"101","author":"Tsai JN","year":"2016","unstructured":"Tsai JN, Uihlein AV, Burnett-Bowie SM, et al.. Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study). J Clin Endocrinol Metab. 2016, 101:2023-30. 10.1210\/jc.2016-1160","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S333207","article-title":"The effect of daily teriparatide versus one-time annually zoledronic acid administration after transforaminal lumbar interbody fusion in osteoporotic patients","volume":"16","author":"Wang Z","year":"2021","unstructured":"Wang Z, Zhuang C, Chen W, et al.. The effect of daily teriparatide versus one-time annually zoledronic acid administration after transforaminal lumbar interbody fusion in osteoporotic patients. Clin Interv Aging. 2021, 16:1789-99. 10.2147\/CIA.S333207","journal-title":"Clin Interv Aging"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake MT","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008, 83:1032-45. 10.4065\/83.9.1032","journal-title":"Mayo Clin Proc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0376-2491.2018.32.010","article-title":"Clinical significance of the ratio of serum beta-CTX\/PINP in multiple myeloma bone diseases and bone metastases (Article in Chinese)","volume":"98","author":"Yang SW","year":"2018","unstructured":"Yang SW, Ma RJ, Zhao JJ, et al.. Clinical significance of the ratio of serum beta-CTX\/PINP in multiple myeloma bone diseases and bone metastases (Article in Chinese). Zhonghua Yi Xue Za Zhi. 2018, 98:2583-7. 10.3760\/cma.j.issn.0376-2491.2018.32.010","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-005-2025-y","article-title":"Changes in bone mass and bone turnover following tibial shaft fracture","volume":"17","author":"Veitch SW","year":"2006","unstructured":"Veitch SW, Findlay SC, Hamer AJ, Blumsohn A, Eastell R, Ingle BM. Changes in bone mass and bone turnover following tibial shaft fracture. Osteoporos Int. 2006, 17:364-72. 10.1007\/s00198-005-2025-y","journal-title":"Osteoporos Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S141097","article-title":"Lower serum P1NP\/\u03b2CTX ratio and hypoalbuminemia are independently associated with osteoporotic nonvertebral fractures in older adults","volume":"12","author":"Fisher A","year":"2017","unstructured":"Fisher A, Srikusalanukul W, Fisher L, Smith PN. Lower serum P1NP\/\u03b2CTX ratio and hypoalbuminemia are independently associated with osteoporotic nonvertebral fractures in older adults. Clin Interv Aging. 2017, 12:1131-40. 10.2147\/CIA.S141097","journal-title":"Clin Interv Aging"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhsa.2016.12.003","article-title":"Elevated bone turnover markers are associated with distal radius fractures in premenopausal women","volume":"42","author":"Ting BL","year":"2017","unstructured":"Ting BL, Walley KC, Travison TG, Rozental TD. Elevated bone turnover markers are associated with distal radius fractures in premenopausal women. J Hand Surg Am. 2017, 42:71-7. 10.1016\/j.jhsa.2016.12.003","journal-title":"J Hand Surg Am"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2241","article-title":"The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women","volume":"94","author":"Grey A","year":"2009","unstructured":"Grey A, Bolland MJ, Wattie D, Horne A, Gamble G, Reid IR. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab. 2009, 94:538-44. 10.1210\/jc.2008-2241","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14487","article-title":"Quantitative prediction of bone mineral density by using bone turnover markers in response to antiresorptive agents in postmenopausal osteoporosis: a model-based meta-analysis","volume":"87","author":"Wu J","year":"2021","unstructured":"Wu J, Wang C, Li GF, Tang ET, Zheng Q. Quantitative prediction of bone mineral density by using bone turnover markers in response to antiresorptive agents in postmenopausal osteoporosis: a model-based meta-analysis. Br J Clin Pharmacol. 2021, 87:1175-86. 10.1111\/bcp.14487","journal-title":"Br J Clin Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S138000","article-title":"A comprehensive overview on osteoporosis and its risk factors","volume":"14","author":"Pouresmaeili F","year":"2018","unstructured":"Pouresmaeili F, Kamalidehghan B, Kamarehei M, Goh YM. A comprehensive overview on osteoporosis and its risk factors. Ther Clin Risk Manag. 2018, 14:2029-49. 10.2147\/TCRM.S138000","journal-title":"Ther Clin Risk Manag"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.6782","article-title":"Comparison of bone turnover markers between young adult male smokers and nonsmokers","volume":"12","author":"Al-Bashaireh AM","year":"2020","unstructured":"Al-Bashaireh AM, Alqudah O. Comparison of bone turnover markers between young adult male smokers and nonsmokers. Cureus. 2020, 12:e6782. 10.7759\/cureus.6782","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1206235","article-title":"The effect of tobacco smoking on bone mass: an overview of pathophysiologic mechanisms","volume":"2018","author":"Al-Bashaireh AM","year":"2018","unstructured":"Al-Bashaireh AM, Haddad LG, Weaver M, Chengguo X, Kelly DL, Yoon S. The effect of tobacco smoking on bone mass: an overview of pathophysiologic mechanisms. J Osteoporos. 2018, 2018:1206235. 10.1155\/2018\/1206235","journal-title":"J Osteoporos"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid IR","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P, et al.. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002, 346:653-61. 10.1056\/NEJMoa011807","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.3.8325","article-title":"Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis","volume":"87","author":"Johnell O","year":"2002","unstructured":"Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002, 87:985-92. 10.1210\/jcem.87.3.8325","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-012-1984-z","article-title":"Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan","volume":"24","author":"Soong YK","year":"2013","unstructured":"Soong YK, Tsai KS, Huang HY, et al.. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporos Int. 2013, 24:511-21. 10.1007\/s00198-012-1984-z","journal-title":"Osteoporos Int"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-013-2395-5","article-title":"Bisphosphonate use and subsequent hip fracture in South Korea","volume":"24","author":"Lee YK","year":"2013","unstructured":"Lee YK, Ha YC, Choi HJ, et al.. Bisphosphonate use and subsequent hip fracture in South Korea. Osteoporos Int. 2013, 24:2887-92. 10.1007\/s00198-013-2395-5","journal-title":"Osteoporos Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/os.12460","article-title":"Study on zoledronic acid reducing acute bone loss and fracture rates in elderly postoperative patients with intertrochanteric fractures","volume":"11","author":"Liu Z","year":"2019","unstructured":"Liu Z, Li CW, Mao YF, et al.. Study on zoledronic acid reducing acute bone loss and fracture rates in elderly postoperative patients with intertrochanteric fractures. Orthop Surg. 2019, 11:380-5. 10.1111\/os.12460","journal-title":"Orthop Surg"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3415-4","article-title":"Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study","volume":"27","author":"Brozek W","year":"2016","unstructured":"Brozek W, Reichardt B, Zwerina J, Dimai HP, Klaushofer K, Zwettler E. Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study. Osteoporos Int. 2016, 27:387-96. 10.1007\/s00198-015-3415-4","journal-title":"Osteoporos Int"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-019-00611-3","article-title":"Treatment effects of bisphosphonates and denosumab on survival and refracture from real-world data of hip-fractured patients","volume":"105","author":"Behanova M","year":"2019","unstructured":"Behanova M, Reichardt B, Stamm TA, Zwerina J, Klaushofer K, Kocijan R. Treatment effects of bisphosphonates and denosumab on survival and refracture from real-world data of hip-fractured patients. Calcif Tissue Int. 2019, 105:630-41. 10.1007\/s00223-019-00611-3","journal-title":"Calcif Tissue Int"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.688269","article-title":"The effect of bisphosphonates on fracture healing time and changes in bone mass density: a meta-analysis","volume":"12","author":"Gao Y","year":"2021","unstructured":"Gao Y, Liu X, Gu Y, et al.. The effect of bisphosphonates on fracture healing time and changes in bone mass density: a meta-analysis. Front Endocrinol (Lausanne). 2021, 12:688269. 10.3389\/fendo.2021.688269","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study","volume":"20","author":"Rosen CJ","year":"2005","unstructured":"Rosen CJ, Hochberg MC, Bonnick SL, et al.. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res. 2005, 20:141-51. 10.1359\/JBMR.040920","journal-title":"J Bone Miner Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12429","article-title":"Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis","volume":"41","author":"Tan W","year":"2016","unstructured":"Tan W, Sun J, Zhou L, Li Y, Wu X. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis. J Clin Pharm Ther. 2016, 41:519-23. 10.1111\/jcpt.12429","journal-title":"J Clin Pharm Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell R","year":"2003","unstructured":"Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003, 18:1051-6. 10.1359\/jbmr.2003.18.6.1051","journal-title":"J Bone Miner Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial","volume":"19","author":"Bauer DC","year":"2004","unstructured":"Bauer DC, Black DM, Garnero P, et al.. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004, 19:1250-8. 10.1359\/JBMR.040512","journal-title":"J Bone Miner Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black DM","year":"2012","unstructured":"Black DM, Reid IR, Boonen S, et al.. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012, 27:243-54. 10.1002\/jbmr.1494","journal-title":"J Bone Miner Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-020-01180-4","article-title":"Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study","volume":"39","author":"Tanaka S","year":"2021","unstructured":"Tanaka S, Mizutani H, Tsuruya E, Fukuda R, Kuge K, Okubo N. Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study. J Bone Miner Metab. 2021, 39:463-73. 10.1007\/s00774-020-01180-4","journal-title":"J Bone Miner Metab"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2011.10.024","article-title":"Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate","volume":"50","author":"Sambrook PN","year":"2012","unstructured":"Sambrook PN, Roux C, Devogelaer JP, et al.. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone. 2012, 50:289-95. 10.1016\/j.bone.2011.10.024","journal-title":"Bone"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-009-1062-3","article-title":"Does standardized BMD still remove differences between Hologic and GE-Lunar state-of-the-art DXA systems?","volume":"21","author":"Fan B","year":"2010","unstructured":"Fan B, Lu Y, Genant H, Fuerst T, Shepherd J. Does standardized BMD still remove differences between Hologic and GE-Lunar state-of-the-art DXA systems?. Osteoporos Int. 2010, 21:1227-36. 10.1007\/s00198-009-1062-3","journal-title":"Osteoporos Int"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2016.020","article-title":"Bone mineral density: testing for osteoporosis","volume":"39","author":"Sheu A","year":"2016","unstructured":"Sheu A, Diamond T. Bone mineral density: testing for osteoporosis. Aust Prescr. 2016, 39:35-9. 10.18773\/austprescr.2016.020","journal-title":"Aust Prescr"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000001920","article-title":"Declining serum bone turnover markers are associated with the short-term positive change of lumbar spine bone mineral density in postmenopausal women","volume":"29","author":"Zhao S","year":"2022","unstructured":"Zhao S, Mo X, Wen Z, et al.. Declining serum bone turnover markers are associated with the short-term positive change of lumbar spine bone mineral density in postmenopausal women. Menopause. 2022, 29:335-43. 10.1097\/GME.0000000000001920","journal-title":"Menopause"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnac031","article-title":"Bone turnover markers: basic biology to clinical applications","volume":"44","author":"Schini M","year":"2023","unstructured":"Schini M, Vilaca T, Gossiel F, Salam S, Eastell R. Bone turnover markers: basic biology to clinical applications. Endocr Rev. 2023, 44:417-73. 10.1210\/endrev\/bnac031","journal-title":"Endocr Rev"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6690095","article-title":"Exploring the relationship of bone turnover markers and bone mineral density in community-dwelling postmenopausal women","volume":"2021","author":"Wei X","year":"2021","unstructured":"Wei X, Zhang Y, Xiang X, et al.. Exploring the relationship of bone turnover markers and bone mineral density in community-dwelling postmenopausal women. Dis Markers. 2021, 2021:6690095. 10.1155\/2021\/6690095","journal-title":"Dis Markers"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-020-00749-w","article-title":"Early changes in bone turnover predict longer-term changes in bone mineral density but not trabecular bone score in frail older women","volume":"15","author":"Kotlarczyk MP","year":"2020","unstructured":"Kotlarczyk MP, Perera S, Resnick NM, Nace DA, Greenspan SL. Early changes in bone turnover predict longer-term changes in bone mineral density but not trabecular bone score in frail older women. Arch Osteoporos. 2020, 15:79. 10.1007\/s11657-020-00749-w","journal-title":"Arch Osteoporos"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3145-7","article-title":"Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study","volume":"27","author":"Naylor KE","year":"2016","unstructured":"Naylor KE, Jacques RM, Paggiosi M, et al.. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int. 2016, 27:21-31. 10.1007\/s00198-015-3145-7","journal-title":"Osteoporos Int"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1644","article-title":"Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Jacques RM","year":"2012","unstructured":"Jacques RM, Boonen S, Cosman F, Reid IR, Bauer DC, Black DM, Eastell R. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012, 27:1627-34. 10.1002\/jbmr.1644","journal-title":"J Bone Miner Res"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-019-1100-6","article-title":"Reference markers of bone turnover for prediction of fracture: a meta-analysis","volume":"14","author":"Tian A","year":"2019","unstructured":"Tian A, Ma J, Feng K, et al.. Reference markers of bone turnover for prediction of fracture: a meta-analysis. J Orthop Surg Res. 2019, 14:68. 10.1186\/s13018-019-1100-6","journal-title":"J Orthop Surg Res"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran S","year":"2011","unstructured":"Vasikaran S, Eastell R, Bruy\u00e8re O, et al.. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011, 22:391-420. 10.1007\/s00198-010-1501-1","journal-title":"Osteoporos Int"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2021.970","article-title":"Operationalizing treat-to-target for osteoporosis","volume":"36","author":"Lewiecki EM","year":"2021","unstructured":"Lewiecki EM. Operationalizing treat-to-target for osteoporosis. Endocrinol Metab (Seoul). 2021, 36:270-8. 10.3803\/EnM.2021.970","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-0756.2008.00868.x","article-title":"Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women","volume":"35","author":"Trento LK","year":"2009","unstructured":"Trento LK, Pietropolli A, Ticconi C, et al.. Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women. J Obstet Gynaecol Res. 2009, 35:152-9. 10.1111\/j.1447-0756.2008.00868.x","journal-title":"J Obstet Gynaecol Res"},{"key":"ref42","article-title":"Bone turnover markers","volume":"42","author":"Coates P","year":"2013","unstructured":"Coates P. Bone turnover markers. Aust Fam Physician. 2013, 42:285-7.","journal-title":"Aust Fam Physician"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2009.12.032","article-title":"Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate","volume":"46","author":"Burshell AL","year":"2010","unstructured":"Burshell AL, M\u00f6ricke R, Correa-Rotter R, et al.. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone. 2010, 46:935-9. 10.1016\/j.bone.2009.12.032","journal-title":"Bone"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s00402-022-04406-4","article-title":"Predisposing factors for a second fragile hip fracture in a population of 1130 patients with hip fractures, treated at Oulu University Hospital in 2013-2016: a retrospective study","volume":"143","author":"Helynen N","year":"2023","unstructured":"Helynen N, Rantanen L, Lehenkari P, Valkealahti M. Predisposing factors for a second fragile hip fracture in a population of 1130 patients with hip fractures, treated at Oulu University Hospital in 2013-2016: a retrospective study. Arch Orthop Trauma Surg. 2023, 143:2261-71. 10.1007\/s00402-022-04406-4","journal-title":"Arch Orthop Trauma Surg"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01063-9","article-title":"Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment and follow-up of treatment for osteoporosis","volume":"36","author":"Lorentzon M","year":"2019","unstructured":"Lorentzon M, Branco J, Brandi ML, et al.. Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment and follow-up of treatment for osteoporosis. Adv Ther. 2019, 36:2811-24. 10.1007\/s12325-019-01063-9","journal-title":"Adv Ther"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.92B3.22787","article-title":"Bone-turnover markers in fracture healing","volume":"92","author":"Cox G","year":"2010","unstructured":"Cox G, Einhorn TA, Tzioupis C, Giannoudis PV. Bone-turnover markers in fracture healing. J Bone Joint Surg Br. 2010, 92:329-34. 10.1302\/0301-620X.92B3.22787","journal-title":"J Bone Joint Surg Br"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06457-0","article-title":"Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study","volume":"33","author":"B\u00f8nl\u00f8kke SE","year":"2022","unstructured":"B\u00f8nl\u00f8kke SE, Rand MS, Haddock B, et al.. Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study. Osteoporos Int. 2022, 33:2155-64. 10.1007\/s00198-022-06457-0","journal-title":"Osteoporos Int"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2019.03.004","article-title":"Consensus statement on the use of bone turnover markers for short-term monitoring of osteoporosis treatment in the Asia-Pacific region","volume":"24","author":"Wu CH","year":"2021","unstructured":"Wu CH, Chang YF, Chen CH, et al.. Consensus statement on the use of bone turnover markers for short-term monitoring of osteoporosis treatment in the Asia-Pacific region. J Clin Densitom. 2021, 24:3-13. 10.1016\/j.jocd.2019.03.004","journal-title":"J Clin Densitom"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2018.03.016","article-title":"Bone turnover markers after the menopause: T-score approach","volume":"111","author":"Gossiel F","year":"2018","unstructured":"Gossiel F, Altaher H, Reid DM, et al.. Bone turnover markers after the menopause: T-score approach. Bone. 2018, 111:44-8. 10.1016\/j.bone.2018.03.016","journal-title":"Bone"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.22747","article-title":"Bone turnover status: classification model and clinical implications","volume":"15","author":"Fisher A","year":"2018","unstructured":"Fisher A, Fisher L, Srikusalanukul W, Smith PN. Bone turnover status: classification model and clinical implications. Int J Med Sci. 2018, 15:323-38. 10.7150\/ijms.22747","journal-title":"Int J Med Sci"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-12-167","article-title":"Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice","volume":"12","author":"Eekman DA","year":"2011","unstructured":"Eekman DA, Bultink IE, Heijboer AC, Dijkmans BA, Lems WF. Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice. BMC Musculoskelet Disord. 2011, 12:167. 10.1186\/1471-2474-12-167","journal-title":"BMC Musculoskelet Disord"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2010.01.007","article-title":"The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy","volume":"13","author":"Hochberg MC","year":"2010","unstructured":"Hochberg MC, Silverman SL, Barr CE, Miller PD. The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy. J Clin Densitom. 2010, 13:181-9. 10.1016\/j.jocd.2010.01.007","journal-title":"J Clin Densitom"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-65-770-127","article-title":"Measurement of forearm bone mineral density in normal women by dual-energy X-ray absorptiometry","volume":"65","author":"Ryan PJ","year":"1992","unstructured":"Ryan PJ, Blake GM, Fogelman I. Measurement of forearm bone mineral density in normal women by dual-energy X-ray absorptiometry. Br J Radiol. 1992, 65:127-31. 10.1259\/0007-1285-65-770-127","journal-title":"Br J Radiol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1101\/383935","article-title":"Reaction times and other skewed distributions: problems with the mean and the median","author":"Rousselet GA","year":"2018","unstructured":"Rousselet GA, Wilcox RR. Reaction times and other skewed distributions: problems with the mean and the median. Neuroscience. 2018, 201820269. 10.1101\/383935","journal-title":"Neuroscience"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/465330-role-of-bone-turnover-markers-and-bone-mineral-density-in-monitoring-bone-health-at-one--and-three-year-post-antiresorptive-therapy-initiation-in-patients-with-osteoporosis-a-retrospective-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T06:42:41Z","timestamp":1774248161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/465330-role-of-bone-turnover-markers-and-bone-mineral-density-in-monitoring-bone-health-at-one--and-three-year-post-antiresorptive-therapy-initiation-in-patients-with-osteoporosis-a-retrospective-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,22]]},"references-count":54,"URL":"https:\/\/doi.org\/10.7759\/cureus.105675","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,22]]}}}